Genetic and Epigenetic Alterations in Primary-Progressive Paired Oligodendroglial Tumors

Lu Ting Kuo, Shao Yu Tsai, Cheng Chi Chang, Kuang Ting Kuo, Abel Po Hao Huang, Jui Chang Tsai, Ham Min Tseng, Meng Fai Kuo, Yong Kwang Tu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of the present study was to identify genetic and epigenetic alterations involved in the progression of oligodendroglial tumors. We characterized 21 paired, World Health Organization (WHO) grade II and III oligodendroglial tumors from patients who received craniotomies for the partial or complete resection of primary and secondary oligodendroglial tumors. Tumor DNA was analyzed for alterations in selected genetic loci (1p36, 9p22, 10q23-24, 17p13, 19q13, 22q12), isocitrate dehydrogenase 1 (IDH1), isocitrate dehydrogenase 2 (IDH2) and the CpG island methylation status of critical tumor-related genes (MGMT, P16, DAPK, PTEN, RASSF1A, Rb1). Alterations of these markers were common early in the tumorigenesis. In the primary tumors we identified 12 patients (57.1%) with 1p36 deletions, 17 (81.0%) with 19q13 deletions, 9 (42.9%) with 1p36/19q13 codeletions, 11 (52.3%) with 9p22 deletions, and 12 (57.1%) with IDH1 mutation. Epigenetic analysis detected promoter methylation of the MGMT, P16, DAPK, PTEN, RASSF1A, and Rb1 genes in 38.1%, 19.0%, 38.1%, 33.3%, 66.7%, and 14.3% of primary tumors, respectively. After progression, additional losses of 1p, 9p, 10q, 17p, 19q and 22q were observed in 3 (14.3%), 1 (4.8%), 3 (14.3%), 2 (9.5%), 1 (4.8%) and 3 (14.3%) cases, respectively. Additional methylations of the MGMT, P16, DAPK, PTEN, RASSF1A, and RB1 promoters was observed in 4 (19.0%), 2 (9.5%), 0 (0%), 6 (28.6%), 2(9.5%) and 3 (14.3%) cases, respectively. The status of IDH1 mutation remained unchanged in all tumors after progression. The primary tumors of three patients with subsequent progression to high-grade astrocytomas, all had 9p deletion, intact 1p, intact 10q and unmethylated MGMT. Whether this may represent a molecular signature of patients at-risk for the development of aggressive astrocytomas needs further investigation.

Original languageEnglish
Article numbere67139
JournalPLoS One
Volume8
Issue number6
DOIs
Publication statusPublished - Jun 24 2013
Externally publishedYes

Fingerprint

Epigenomics
epigenetics
Tumors
neoplasms
Isocitrate Dehydrogenase
isocitrate dehydrogenase
Neoplasms
Methylation
methylation
Astrocytoma
Genes
promoter regions
p16 Genes
mutation
Mutation
CpG Islands
Genetic Loci
Craniotomy
World Health Organization
resection

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Kuo, L. T., Tsai, S. Y., Chang, C. C., Kuo, K. T., Huang, A. P. H., Tsai, J. C., ... Tu, Y. K. (2013). Genetic and Epigenetic Alterations in Primary-Progressive Paired Oligodendroglial Tumors. PLoS One, 8(6), [e67139]. https://doi.org/10.1371/journal.pone.0067139

Genetic and Epigenetic Alterations in Primary-Progressive Paired Oligodendroglial Tumors. / Kuo, Lu Ting; Tsai, Shao Yu; Chang, Cheng Chi; Kuo, Kuang Ting; Huang, Abel Po Hao; Tsai, Jui Chang; Tseng, Ham Min; Kuo, Meng Fai; Tu, Yong Kwang.

In: PLoS One, Vol. 8, No. 6, e67139, 24.06.2013.

Research output: Contribution to journalArticle

Kuo, LT, Tsai, SY, Chang, CC, Kuo, KT, Huang, APH, Tsai, JC, Tseng, HM, Kuo, MF & Tu, YK 2013, 'Genetic and Epigenetic Alterations in Primary-Progressive Paired Oligodendroglial Tumors', PLoS One, vol. 8, no. 6, e67139. https://doi.org/10.1371/journal.pone.0067139
Kuo, Lu Ting ; Tsai, Shao Yu ; Chang, Cheng Chi ; Kuo, Kuang Ting ; Huang, Abel Po Hao ; Tsai, Jui Chang ; Tseng, Ham Min ; Kuo, Meng Fai ; Tu, Yong Kwang. / Genetic and Epigenetic Alterations in Primary-Progressive Paired Oligodendroglial Tumors. In: PLoS One. 2013 ; Vol. 8, No. 6.
@article{dea1f800d5c34fe892a1226191c0e0ac,
title = "Genetic and Epigenetic Alterations in Primary-Progressive Paired Oligodendroglial Tumors",
abstract = "The aim of the present study was to identify genetic and epigenetic alterations involved in the progression of oligodendroglial tumors. We characterized 21 paired, World Health Organization (WHO) grade II and III oligodendroglial tumors from patients who received craniotomies for the partial or complete resection of primary and secondary oligodendroglial tumors. Tumor DNA was analyzed for alterations in selected genetic loci (1p36, 9p22, 10q23-24, 17p13, 19q13, 22q12), isocitrate dehydrogenase 1 (IDH1), isocitrate dehydrogenase 2 (IDH2) and the CpG island methylation status of critical tumor-related genes (MGMT, P16, DAPK, PTEN, RASSF1A, Rb1). Alterations of these markers were common early in the tumorigenesis. In the primary tumors we identified 12 patients (57.1{\%}) with 1p36 deletions, 17 (81.0{\%}) with 19q13 deletions, 9 (42.9{\%}) with 1p36/19q13 codeletions, 11 (52.3{\%}) with 9p22 deletions, and 12 (57.1{\%}) with IDH1 mutation. Epigenetic analysis detected promoter methylation of the MGMT, P16, DAPK, PTEN, RASSF1A, and Rb1 genes in 38.1{\%}, 19.0{\%}, 38.1{\%}, 33.3{\%}, 66.7{\%}, and 14.3{\%} of primary tumors, respectively. After progression, additional losses of 1p, 9p, 10q, 17p, 19q and 22q were observed in 3 (14.3{\%}), 1 (4.8{\%}), 3 (14.3{\%}), 2 (9.5{\%}), 1 (4.8{\%}) and 3 (14.3{\%}) cases, respectively. Additional methylations of the MGMT, P16, DAPK, PTEN, RASSF1A, and RB1 promoters was observed in 4 (19.0{\%}), 2 (9.5{\%}), 0 (0{\%}), 6 (28.6{\%}), 2(9.5{\%}) and 3 (14.3{\%}) cases, respectively. The status of IDH1 mutation remained unchanged in all tumors after progression. The primary tumors of three patients with subsequent progression to high-grade astrocytomas, all had 9p deletion, intact 1p, intact 10q and unmethylated MGMT. Whether this may represent a molecular signature of patients at-risk for the development of aggressive astrocytomas needs further investigation.",
author = "Kuo, {Lu Ting} and Tsai, {Shao Yu} and Chang, {Cheng Chi} and Kuo, {Kuang Ting} and Huang, {Abel Po Hao} and Tsai, {Jui Chang} and Tseng, {Ham Min} and Kuo, {Meng Fai} and Tu, {Yong Kwang}",
year = "2013",
month = "6",
day = "24",
doi = "10.1371/journal.pone.0067139",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Genetic and Epigenetic Alterations in Primary-Progressive Paired Oligodendroglial Tumors

AU - Kuo, Lu Ting

AU - Tsai, Shao Yu

AU - Chang, Cheng Chi

AU - Kuo, Kuang Ting

AU - Huang, Abel Po Hao

AU - Tsai, Jui Chang

AU - Tseng, Ham Min

AU - Kuo, Meng Fai

AU - Tu, Yong Kwang

PY - 2013/6/24

Y1 - 2013/6/24

N2 - The aim of the present study was to identify genetic and epigenetic alterations involved in the progression of oligodendroglial tumors. We characterized 21 paired, World Health Organization (WHO) grade II and III oligodendroglial tumors from patients who received craniotomies for the partial or complete resection of primary and secondary oligodendroglial tumors. Tumor DNA was analyzed for alterations in selected genetic loci (1p36, 9p22, 10q23-24, 17p13, 19q13, 22q12), isocitrate dehydrogenase 1 (IDH1), isocitrate dehydrogenase 2 (IDH2) and the CpG island methylation status of critical tumor-related genes (MGMT, P16, DAPK, PTEN, RASSF1A, Rb1). Alterations of these markers were common early in the tumorigenesis. In the primary tumors we identified 12 patients (57.1%) with 1p36 deletions, 17 (81.0%) with 19q13 deletions, 9 (42.9%) with 1p36/19q13 codeletions, 11 (52.3%) with 9p22 deletions, and 12 (57.1%) with IDH1 mutation. Epigenetic analysis detected promoter methylation of the MGMT, P16, DAPK, PTEN, RASSF1A, and Rb1 genes in 38.1%, 19.0%, 38.1%, 33.3%, 66.7%, and 14.3% of primary tumors, respectively. After progression, additional losses of 1p, 9p, 10q, 17p, 19q and 22q were observed in 3 (14.3%), 1 (4.8%), 3 (14.3%), 2 (9.5%), 1 (4.8%) and 3 (14.3%) cases, respectively. Additional methylations of the MGMT, P16, DAPK, PTEN, RASSF1A, and RB1 promoters was observed in 4 (19.0%), 2 (9.5%), 0 (0%), 6 (28.6%), 2(9.5%) and 3 (14.3%) cases, respectively. The status of IDH1 mutation remained unchanged in all tumors after progression. The primary tumors of three patients with subsequent progression to high-grade astrocytomas, all had 9p deletion, intact 1p, intact 10q and unmethylated MGMT. Whether this may represent a molecular signature of patients at-risk for the development of aggressive astrocytomas needs further investigation.

AB - The aim of the present study was to identify genetic and epigenetic alterations involved in the progression of oligodendroglial tumors. We characterized 21 paired, World Health Organization (WHO) grade II and III oligodendroglial tumors from patients who received craniotomies for the partial or complete resection of primary and secondary oligodendroglial tumors. Tumor DNA was analyzed for alterations in selected genetic loci (1p36, 9p22, 10q23-24, 17p13, 19q13, 22q12), isocitrate dehydrogenase 1 (IDH1), isocitrate dehydrogenase 2 (IDH2) and the CpG island methylation status of critical tumor-related genes (MGMT, P16, DAPK, PTEN, RASSF1A, Rb1). Alterations of these markers were common early in the tumorigenesis. In the primary tumors we identified 12 patients (57.1%) with 1p36 deletions, 17 (81.0%) with 19q13 deletions, 9 (42.9%) with 1p36/19q13 codeletions, 11 (52.3%) with 9p22 deletions, and 12 (57.1%) with IDH1 mutation. Epigenetic analysis detected promoter methylation of the MGMT, P16, DAPK, PTEN, RASSF1A, and Rb1 genes in 38.1%, 19.0%, 38.1%, 33.3%, 66.7%, and 14.3% of primary tumors, respectively. After progression, additional losses of 1p, 9p, 10q, 17p, 19q and 22q were observed in 3 (14.3%), 1 (4.8%), 3 (14.3%), 2 (9.5%), 1 (4.8%) and 3 (14.3%) cases, respectively. Additional methylations of the MGMT, P16, DAPK, PTEN, RASSF1A, and RB1 promoters was observed in 4 (19.0%), 2 (9.5%), 0 (0%), 6 (28.6%), 2(9.5%) and 3 (14.3%) cases, respectively. The status of IDH1 mutation remained unchanged in all tumors after progression. The primary tumors of three patients with subsequent progression to high-grade astrocytomas, all had 9p deletion, intact 1p, intact 10q and unmethylated MGMT. Whether this may represent a molecular signature of patients at-risk for the development of aggressive astrocytomas needs further investigation.

UR - http://www.scopus.com/inward/record.url?scp=84879477039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879477039&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0067139

DO - 10.1371/journal.pone.0067139

M3 - Article

C2 - 23826216

AN - SCOPUS:84879477039

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e67139

ER -